Clinical Trial Update: Phase I/II Trial of IMA950 Multi-peptide Vaccine Plus Poly-ICLC in Glioblastoma [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase I/II clinical trial evaluating IMA950 multi-peptide vaccine plus Poly-ICLC in adults with glioblastoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• IMA950
• Poly-ICLC (poly-ICLC)

Snippet

Sponsor: University Hospital, Geneva | Conditions: CNS Tumor, Adult | Phase 1, Phase 2 | Status: COMPLETED